Who owns ARROWHEAD PHARMACEUTICALS, INC. (ARWR)? Elite investor 13F holders

4 tracked elite investors reported holding ARROWHEAD PHARMACEUTICALS, INC as of 2026-09-30, including Renaissance Technologies LLC, D.E. Shaw, Oaktree Capital Management, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

4 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3,…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Renaissance Technologies LLCARROWHEAD PHARMACEUTICALS INSHARE2026-09-302026-11-12 00:00:002225300.00 USD34000.000000SharesreduceOriginal filing
D.E. ShawARROWHEAD PHARMACEUTICALS INSHARE2026-09-302026-11-16 00:00:0010388158.00 USD158719.000000SharesreduceOriginal filing
Oaktree Capital ManagementARROWHEAD PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:0010951820.00 USD9146000.000000PrincipalbuyOriginal filing
Gotham Asset ManagementARROWHEAD PHARMACEUTICALS INSHARE2026-09-302026-11-16 00:00:00629629.00 USD9620.000000SharesaddOriginal filing
Polen Capital ManagementARROWHEAD PHARMACEUTICALS INSHARE2026-09-302026-11-13 00:00:000.00 USD0.000000SharesexitedOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown